PL1854477T3 - Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych - Google Patents

Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych

Info

Publication number
PL1854477T3
PL1854477T3 PL07005182T PL07005182T PL1854477T3 PL 1854477 T3 PL1854477 T3 PL 1854477T3 PL 07005182 T PL07005182 T PL 07005182T PL 07005182 T PL07005182 T PL 07005182T PL 1854477 T3 PL1854477 T3 PL 1854477T3
Authority
PL
Poland
Prior art keywords
treatment
plasma kallikrein
ophthalmic disorders
inhibiting plasma
peptides inhibiting
Prior art date
Application number
PL07005182T
Other languages
English (en)
Inventor
Pierre Belichard
Original Assignee
Dyax Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp. filed Critical Dyax Corp.
Publication of PL1854477T3 publication Critical patent/PL1854477T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL07005182T 2006-03-16 2007-03-13 Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych PL1854477T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06291516 2006-09-26

Publications (1)

Publication Number Publication Date
PL1854477T3 true PL1854477T3 (pl) 2017-02-28

Family

ID=38292592

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07005182T PL1854477T3 (pl) 2006-03-16 2007-03-13 Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych

Country Status (12)

Country Link
US (3) US20070270344A1 (pl)
JP (2) JP5337493B2 (pl)
AU (1) AU2007224643B2 (pl)
CA (1) CA2646285C (pl)
DK (1) DK1854477T3 (pl)
ES (2) ES2682646T3 (pl)
HU (2) HUE031701T2 (pl)
LT (2) LT2374472T (pl)
PL (1) PL1854477T3 (pl)
PT (2) PT1854477T (pl)
SI (1) SI2374472T1 (pl)
WO (1) WO2007104541A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
PT1941867E (pt) 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT1663281E (pt) * 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
ES2524015T3 (es) 2005-12-30 2014-12-03 Dyax Corporation Proteínas de enlazamiento a la metaloproteinasa
SI2374472T1 (sl) 2006-03-16 2018-11-30 Dyax Corp., Sestavki in postopki za zdravljenje oftalmoloških motenj
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
WO2010048432A1 (en) * 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
HRP20181419T1 (hr) 2010-01-06 2018-11-16 Dyax Corp. Plazma kalikrein vezni proteini
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
CN105683211B (zh) 2013-10-28 2020-10-20 拜斯科阿迪有限公司 新型多肽
CN106132442B (zh) 2014-01-21 2023-07-14 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
KR102555955B1 (ko) * 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017087018A1 (en) * 2015-11-18 2017-05-26 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
JP7668227B2 (ja) * 2019-04-08 2025-04-24 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 血漿カリクレイン阻害剤および眼障害におけるその使用方法
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69533472T2 (de) * 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
DE69533544T2 (de) * 1994-01-11 2006-02-23 Dyax Corp., Cambridge Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
CN1646154B (zh) 2002-02-07 2010-12-01 诺维信生物制药英国有限公司 与白蛋白融合的抗-血管生成肽
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT1941867E (pt) * 2002-06-07 2012-02-16 Dyax Corp Polipeptídeo contendo um domínio kunitz modificado
DK2386310T3 (en) 2002-08-28 2019-02-25 Dyax Corp Methods of preserving organs and tissues
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
PT1663281E (pt) 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
WO2005021556A2 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP2009529542A (ja) 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
SI2374472T1 (sl) * 2006-03-16 2018-11-30 Dyax Corp., Sestavki in postopki za zdravljenje oftalmoloških motenj
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
JP2010536883A (ja) 2007-08-23 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders

Also Published As

Publication number Publication date
AU2007224643A1 (en) 2007-09-20
WO2007104541A2 (en) 2007-09-20
LT1854477T (lt) 2016-12-12
JP2009529553A (ja) 2009-08-20
US20100273721A1 (en) 2010-10-28
US9107928B2 (en) 2015-08-18
ES2682646T3 (es) 2018-09-21
CA2646285A1 (en) 2007-09-20
PT2374472T (pt) 2018-08-08
US20070270344A1 (en) 2007-11-22
LT2374472T (lt) 2018-09-25
ES2601554T3 (es) 2017-02-15
US20150368359A1 (en) 2015-12-24
WO2007104541A3 (en) 2008-06-26
JP5337493B2 (ja) 2013-11-06
DK1854477T3 (en) 2016-11-28
AU2007224643B2 (en) 2012-10-11
HUE039108T2 (hu) 2018-12-28
SI2374472T1 (sl) 2018-11-30
CA2646285C (en) 2020-04-28
PT1854477T (pt) 2016-11-10
HUE031701T2 (en) 2017-07-28
JP2012211194A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
PL1854477T3 (pl) Peptydy hamujące kalikreinę osoczową do zastosowania w leczeniu zaburzeń okulistycznych
IL191283A (en) Compositions for treating eye irregularities
IL193747A0 (en) New therapeutic combinations for the treatment of depression
ZA200800464B (en) Peptides for use in the treatment of obesity
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB0602178D0 (en) Therapeutic treatment
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
ZA200901523B (en) Use of extracts for the treatment of viral disorders
IL196667A (en) Use of peptides to prepare a drug to treat inflammation
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
IL199214A0 (en) New combination for use in the treatment of inflammatory disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
GB0608655D0 (en) Therapeutic Treatment
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders
GB0523961D0 (en) The treatment of ophthalmic diseases
SI1854477T1 (sl) Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
GB0610909D0 (en) Therapeutic treatment
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
PL1714647T3 (pl) Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych
GB0602857D0 (en) The treatment of sialorrhoea
GB0610376D0 (en) Therapeutic treatment
EP1956001A4 (en) PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE
GB0700755D0 (en) The Treatment of ophthalmic diseases